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Abstract: Diabetic cardiomyopathy (DCM), a significant contributor to morbidity and 
mortality in diabetic patients, is characterized by ventricular dysfunction, in the absence of 
coronary atherosclerosis and hypertension. There is no specific therapeutic strategy to 
effectively treat patients with DCM, due to a lack of a mechanistic understanding of the 
disease process. Retinoic acid, the active metabolite of vitamin A, is involved in a wide 
range of biological processes, through binding and activation of nuclear receptors: retinoic 
acid receptors (RAR) and retinoid X receptors (RXR). RAR/RXR-mediated signaling has 
been implicated in the regulation of glucose and lipid metabolism. Recently, it has been 
reported that activation of RAR/RXR has an important role in preventing the development 
of diabetic cardiomyopathy, through improving cardiac insulin resistance, inhibition   
of intracellular oxidative stress, NF-κB-mediated inflammatory responses and the   
renin-angiotensin system. Moreover, downregulated RAR/RXR signaling has been 
demonstrated in diabetic myocardium, suggesting that impaired RAR/RXR signaling may 
be a trigger to accelerate diabetes-induced development of DCM. Understanding the 
molecular mechanisms of retinoid receptors in the regulation of cardiac metabolism and 
remodeling under diabetic conditions is important in providing the impetus for generating 
novel therapeutic approaches for the prevention and treatment of diabetes-induced cardiac 
complications and heart failure. 
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1. Introduction 
Diabetic cardiomyopathy (DCM), characterized by alterations in cardiac morphology and function, 
independent of hypertension or coronary disease, is a significant contributor to morbidity and mortality 
associated with diabetes [1,2]. The etiology of DCM is multifactorial and incompletely understood. 
We and others have shown that chronically activated cardiac NF-κB, JNK pathways, impaired insulin 
signaling-induced metabolic disturbances, dysregulated calcium homeostasis and an over-activated 
renin-angiotensin system are emerging as major molecular and metabolic mechanisms for DCM [3–8]. 
There is no specific therapeutic strategy to effectively treat patients with DCM, due to a lack of 
mechanistic details. 
Retinoic acids (RA), the active metabolite of retinol (vitamin A), are involved in the regulation of 
cell proliferation and differentiation, with effects being mediated by two classes of nuclear receptors, 
retinoic acid receptors (RAR) and retinoid X receptors (RXR). Retinoic acid signaling components 
(retinol binding protein 4, retinal, retinoic acid and retinoid receptors) have been implicated in 
modulating the development of obesity, insulin resistance and diabetes [9–15]. Whether retinoic acid 
and RAR/RXR-mediated signaling are of importance in the development of DCM is not well known. 
This review will focus on recent new developments in retinoic acid signaling and diabetes-induced 
cardiac remodeling. 
2. Diabetic Cardiomyopathy 
The epidemic of obesity and a sedentary lifestyle is projected to result in over 439 million 
individuals with diabetes mellitus (DM) worldwide by 2030 [16]. DM is an important and prevalent 
risk factor for congestive heart failure. Indeed, cardiovascular complications are the leading cause of 
diabetes-related morbidity and mortality (65%) [17]. Heart failure (HF) is a syndrome that represents 
the end stage of different forms of heart disease, affecting nearly 5.8 million people in the United 
States, and more than 23 million people worldwide [18]. HF results in high hospitalization rates and 
mortality; up to 40% of patients die within one year of their first hospitalization, resulting in significant 
health and financial burdens on patients and society [19,20]. The Framingham report indicates that 
diabetes increases the risk of heart failure, independent of other contributing risk factors [21,22]. The 
risk of heart failure in diabetic subjects was increased 2.4-fold in men and five-fold in women. This 
risk was independent of age, hypertension, obesity, coronary artery disease and hyperlipidemia. The 
impairment of left ventricular function in diabetic patients without underlying coronary artery disease 
or hypertension is now recognized as a distinct clinical entity termed “diabetic cardiomyopathy” [23], 
which was first described by Rubler et al., who reported data from four diabetic patients with heart 
failure without evidence of hypertension, coronary artery disease, valvular or congenital heart   
disease [24]. Increased left ventricle (LV) diastolic stiffness and relaxation disturbances are recognized 
as the earliest manifestation of diabetes-induced cardiac remodeling and have been noted in 27%–70% J. Clin. Med. 2014, 3 568 
 
 
of asymptomatic diabetic patients [25,26]. Of note, left ventricular hypertrophy, which is a relevant 
prognostic risk factor in heart disease, occurred more frequently in diabetic patients and is a major 
contributor for the increased ventricular stiffness and diastolic dysfunction [27]. LV systolic 
dysfunction supervenes only at later stages of DCM. A decreased LV systolic ejection fraction (LVEF) 
provides a good reflection of the severity of systolic dysfunction and heart failure. Though the 
pathogenesis and pathophysiology of DCM is multifactorial and poorly understood, current evidence 
suggests that diabetes affects cardiac remodeling through a variety of mechanisms (Figure 1), 
including over-activation of the renin-angiotensin system, insulin resistance, metabolic disturbances 
(hyperglycemia, hyperinsulinemia and hyperlipidemia), fibrosis and impairment of calcium 
homeostasis [28–30]. Given the common and increasing prevalence of diabetes in the general 
population, diabetic cardiomyopathy is a significant and growing public health concern. 
Figure 1. The pathophysiology of diabetic cardiomyopathy. Diabetes-induced cardiac 
insulin resistance, glucose/lipid dysmetabolism and activation of the renin-angiotensin 
system promote the development and progression of diabetic cardiomyopathy (DCM).   
ER, endoplasmic reticulum; RAS, renin-angiotensin system. 
 
Diabetic patients may take several years to develop overt DCM. In the early stage, a majority of the 
cases of DCM are subclinical, and patients may not have overt symptoms or signs of disease. Thus, the 
implementation of diagnostic strategies for DCM to identify the disease at its early stages would be 
important in the prevention and early treatment of DCM. Echocardiography and Doppler imaging  
are able to detect significant cardiac abnormalities before the onset of symptomatic HF. Diastolic 
dysfunction, characterized as HF with normal EF, is present in 75% of asymptomatic diabetic   
patients [31]. The mitral inflow patterns, early ventricular filling wave (E-wave) and the late 
ventricular filling wave (A-wave), the E/A ratio, the isovolumetric relaxation time (IVRT), cardiac 
stiffness and myocardial tissue velocities during the cardiac cycle can be assessed by echocardiography 
and tissue Doppler imaging [32,33]. With more sensitive techniques, like strain deformation imaging, J. Clin. Med. 2014, 3 569 
 
 
researchers observed that LV systolic function is impaired despite normal LVEF [34,35] and   
in 28% of patients with normal diastolic function, suggesting that systolic strain alteration may exist 
despite normal diastolic function and that diastolic dysfunction should not be considered the first 
marker of a preclinical form of DCM. Cardiac magnetic resonance imaging (MRI) and positron 
emission tomography (PET) have recently emerged as a highly sensitive imaging tool for detecting 
myocardial metabolic changes, LV wall motion abnormalities, geometry and cardiac hypertrophy [36] 
and may serve as a new technique in the diagnosis of DCM at an early stage. 
Treatment should begin as soon as the diagnosis of diastolic dysfunction is made, to prevent further 
development of heart failure. The management and treatment of DCM have focused on changes   
in lifestyle, improving glycemic control, treatment of dyslipidemia and management of the coexistent 
hypertension, coronary artery disease (CAD) and heart failure [37]. Regular physical exercise and 
limitation of fat and total energy intake remain the cornerstone of the management of overweight 
diabetic patients. Clinical studies have shown that lifestyle changes with diet and/or exercise 
interventions led to a significant decrease in the incidence of DCM among subjects with type 2 
diabetes [38,39]. Hyperglycemia can directly impair biological processes important for the 
maintenance of normal cellular function and serve as the prime driver behind diabetic DCM. 
Improvement of glycemic control has been shown to be associated with better outcomes in diabetic 
microvascular complications in clinical trials [40,41]. However, many prospective randomized clinical 
trials, such as ACCORD (Action to Control Cardiovascular Risk in Diabetes) and ADVANCE (Action 
in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), failed to 
conclusively demonstrate that aggressive glycemic control improves the cardiovascular prognosis of 
diabetic patients, especially those with advanced type 2 diabetes [41–43]. Different drug combinations, 
like metformin plus dipeptidyl peptidase-4 inhibitors/Glucagon-like peptide-1 mimetics, metformin 
plus pioglitazone, sulphonylurea or insulin, may be necessary for optimal glycemic control [37]. 
Treatment of dyslipidemia significantly reduces the incidence of major cardiovascular events, including 
DCM, in type 2 diabetic patients, and a reduction in low density lipoprotein cholesterol should be the 
primary goal for lipid modifying interventions [44,45]. Various vasoactive drugs, such as renin 
inhibitor, angiotensin convertase enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), beta 
adreno-receptor blockers and calcium channel blockers, have been used in the management of 
hypertension, CAD and HF and have been found to be beneficial for patients with DCM [46,47]. 
ACEIs and ARBs have demonstrated cardiovascular protection in diabetic patients [48,49]. Aliskiren 
is the first representative of a new class of orally active direct renin inhibitors and provides a more 
complete blockade of the renin-angiotensin system (RAS), effectively suppressing residual angiotensin II 
production and the counter-regulatory increase in plasma renin activity observed in patients receiving 
monotherapy with ACEIs or ARBs [50]. However, the combination therapy of aliskiren with ACEIs or 
ARBs in diabetic hypertensive patients with chronic kidney disease is controversial [51,52]. Currently, 
a combination therapy of aliskiren with ACEIs and ARBs is not recommended in patients with type 2 
diabetes mellitus and renal impairment. Beta-blockers have been shown to prevent and even reverse 
cardiac remodeling, resulting in improved LV function and a reduction in mortality in diabetic and 
non-diabetic patients [53]. Beta-blockers should be given to all diabetic patients with any evidence of 
HF, unless specifically contraindicated. Calcium channel blockers are capable of reversing the 
intracellular calcium defects and preventing diabetes-induced myocardial changes and are safe and J. Clin. Med. 2014, 3 570 
 
 
effective as first-line or add-on therapies in diabetic hypertensive patients [54]. In addition to diabetic 
and heart failure therapies, other novel treatments are under investigation for DCM. Continued efforts 
to identify effective preventative strategies and treatments are essential. 
3. Retinoic Acid and Retinoid Receptor Signaling 
Retinoic acid (RA), the active metabolite of vitamin A (Figure 2A), is an important signaling 
molecule in embryonic development and in regulating cell survival, differentiation and death [55].  
The precursors of RA have to be obtained from the diet, either as retinyl esters from animal sources or 
β-carotene from plants. In the circulation, retinol binds to the specific transport protein, retinol-binding 
protein 4 (RBP4), and forms a complex with transthyretin to prevent renal filtration and catabolism [56]. 
Retinol is taken up by target cells from the circulation through spontaneous diffusion across plasma 
membranes, fluxes that are dictated by its extracellular to intracellular concentration gradient [57], or 
through a cell surface receptor, STRA6 (stimulated by retinoic acid) [58]. Recent studies have shown 
that STRA6 mediated retinol uptake is only required in eye, and it is not critical for maintaining  
retinol availability in tissues that express it [59,60]. Intracellularly, retinol associates with cellular 
retinol-binding protein (CRBP) and is oxidized to retinaldehyde (rate-limiting) by two types of 
enzymes: alcohol dehydrogenase (ADH) of the medium-chain ADH family and short-chain 
dehydrogenase/reductase (SDR) [61,62]. Studies have demonstrated that the ADH enzymes are   
not essential for RA biosynthesis from a physiologically relevant supply of vitamin A during 
embryogenesis or adulthood and that SDR family members have been implicated in the regulation of 
RA homeostasis [63,64]. Retinaldehyde is further oxidized to all-trans retinoic acid (ATRA), 
irreversibly by retinaldehyde dehydrogenase (RALDH) [65]. After binding to cellular retinoic acid 
binding proteins (CRABP), ATRA is transported into the nucleus and binds to nuclear receptors to 
regulate gene transcription or delivered to cytochrome (CYP) enzymes for degradation [66,67]. Most 
of the biological effects of RA are mediated by retinoic acid receptors (RAR) and retinoid X receptors 
(RXR). Both have three subtypes, α, β and γ, and are members of the nuclear hormone receptor   
super-family. RAR and RXR modulate gene expression by acting as ligand-dependent transcription 
factors. RARs primarily bind to ATRA, and RXRs bind to a stereoisomer, 9-cis-RA. Upon ligand 
binding, receptors form dimers and bind to DNA motifs known as RA response elements (RAREs), 
located in the regulatory regions of target genes and which subsequently modulate the transcription of 
an array of target genes [68,69] RAR is activated only when heterodimerizing with RXRs. RXR 
modulates gene transcription by forming either homodimers or heterodimers with several other nuclear 
receptors, including RAR, the vitamin D receptor, peroxisome proliferator activated receptors 
(PPARs), farnesoid X receptors, the liver X receptor (LXR) and the thyroid hormone receptor. 
Therefore, RXR plays a key role in nuclear signaling pathways involving its dimeric partners. RAR 
and RXR have conserved structures with six regions (A–F) (Figure 2B). The N-terminal A/B region 
contains another transcription activation domain (AF-1) that functions autonomously and ligand 
independently. This domain contains many phosphorylation sites and is the target of multiple kinases. 
The central C region is the most conserved DNA-binding domain (DBD). The C-terminal contains a 
ligand-binding domain (LBD) and ligand-dependent transactivation domain (AF-2). In the absence of a 
ligand, RXR/RAR heterodimers are bound to DNA in a complex with corepressors (such as NCoR J. Clin. Med. 2014, 3 571 
 
 
(nuclear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone) 
receptors) that actively repress transcription. Upon ligand binding, co-repressors are released, and   
co-activator complexes (including p160 family members, the CREB-binding protein and p300) are 
recruited to activate transcription. The transactivation of RAR and RXR is also regulated by 
phosphorylation. Signaling pathways initiated by Cdk7 and PKA are involved in the positive control of 
retinoid-regulated transcription [70,71]. PKC, Akt and JNK-induced phosphorylation leads to degradation 
and transrepression of RAR/RXR [72–74]. Several lines of evidence indicate that phosphorylation of 
RAR/RXR has a crucial role in the development of certain cancers [75,76]. The requirement for 
retinoic acid during embryogenesis (brain, heart, lung and limb formation) has been long   
appreciated [77], and deregulated retinoid signaling contributes to serious diseases, such as cancer and 
metabolic diseases [78–81]. Retinoids have been investigated extensively for their use in cancer 
prevention and treatment [82]. 
Figure 2. Retinoid metabolism and the structure of retinoid receptors. (A) Retinol binds to 
RBP4 (retinol binding protein 4) in plasma. RBP4 bonds to STRA6, resulting in the 
activation of the JAK2 signaling pathway. Retinol bound with cellular retinol-binding 
protein (CRBP) is converted to retinaldehyde by short-chain dehydrogenase/reductase 
(SDR); and then to all-trans retinoic acid (ATRA) by retinaldehyde dehydrogenase 
(RALDH); (B) Schematic representation of the functional domains and the major 
phosphorylation sites of RARα (retinoic acid receptor α) and RXRα (retinoid X   
receptors α). The DNA-binding domain (DBD) and the ligand-binding domain (LBD) are 
schematically represented (not to scale). The functional AF-1 and AF-2 domains lie in the 
A/B and E regions, respectively. Phosphorylation sites are shown in a bold black line. 
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4. Retinoic Acid Signaling Is Involved in the Development of Diabetes 
To date, the impacts of vitamin A and retinoids on the energy metabolism of the liver, adipocytes, 
pancreatic β-cells and skeletal muscle in animals and humans have been demonstrated in basic and 
clinical investigations (Figure 3) [14,15,83–89]. There is increasing evidence that vitamin A 
metabolism is impaired, especially in poorly controlled DM [90,91]. Studies have shown a decreased 
plasma level of retinol in type 1 diabetic patients and in streptozotocin-induced diabetic animal   
models [92,93] and that dietary supplementation of vitamin A inhibits the development of type 1 
diabetes [94]. Van Y. H. et al. reported that ATRA inhibits the development of type 1 diabetes by  
T regulatory-dependent suppression of interferon γ-producing T-cells [95], suggesting that the use of 
ATRA to induce immune tolerance may provide an effective method to inhibit type 1 DM. Although 
the plasma level of retinol is normal in type 2 DM, an increased serum level of RBP4 is observed. The 
increased serum RBP4 concentrations in type 2 diabetic patients may be associated with diabetes-related 
renal dysfunction, cardiovascular disease and imbalances in lipid metabolism [83,96,97]. Lowering the 
RBP4 level by ATRA or a synthetic retinoid, fenretinide, leads to improved insulin action and   
glucose tolerance in insulin-resistant obese mice [91,92,98–100]. Recent studies have shown that   
holo-RBP/STRA6 is involved in the regulation of activation of the JAK2/STAT5 cascade and   
insulin resistance, by inducing the suppressor of cytokine signaling 3 (SOCS3) and PPARγ  
expression [59,101]. RBP4-mediated inhibition of insulin signaling is also regulated by promoting the 
expression of proinflammatory cytokines through a toll-like receptor 4- and c-Jun N-terminal kinase 
(JNK)-dependent and retinol-independent mechanism [10]. Activation of RAR/RXR-mediated 
signaling also has anti-diabetic effects in type 2 DM. In 1997, Mukherjee R. et al. first reported that a 
synthetic activator of RXR functions as an insulin sensitizer, markedly decreasing serum glucose and 
insulin levels in mouse models of type 2 diabetes and obesity [102]. Treatment of diabetic (db/db) 
mice with LG268 (selective RXR ligand) significantly increased insulin-stimulated glucose transport 
in skeletal muscle, via increasing insulin-stimulated insulin receptor substrate 1 (IRS1) tyrosine 
phosphorylation and AKT phosphorylation [103]. Our group also reported that ATRA, Am580 (RARα 
selective ligand) and LGD1069 (RXR ligand) lowered the blood glucose level and improved insulin 
resistance in a Zucker diabetic fatty (ZDF) rat type 2 diabetic model [6,7]. J. Clin. Med. 2014, 3 573 
 
 
Figure 3. Retinoid-mediated signaling in the regulation of glucose/lipid metabolism. The 
schematic diagram represents the involvement of retinoid signaling components in the 
regulation of glucose/lipid metabolism in the development of obesity and diabetes. RBP4, 
retinol binding protein 4; SDR, short-chain dehydrogenase/reductase; RALDH, 
retinaldehyde dehydrogenase; HFD, high fat diet; RALDH−/−, RALDH knockout mice. 
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Obesity has historically been shown to be a risk factor for type 2 diabetes. During the past 50 years, 
both clinical and animal studies have suggested the involvement of retinoids and RAR/RXR signaling 
in the regulation of lipid metabolism and obesity. Supplementation of obese rats with high levels of 
dietary vitamin A reduced body weight gain and visceral adiposity and improved insulin sensitivity, by 
decreasing soleus muscle PTP1B (protein tyrosine phosphatase 1B) levels and increasing insulin 
receptor phosphorylation [104]. Retinoic acid treatment also resulted in weight loss, decreased 
adiposity and increased insulin sensitivity, through promoting lipid oxidation capacity in skeletal 
muscle and liver in several lean and/or obese mouse models [89,105,106]. Similarly, a diet deficient in 
vitamin A led to an increase in body weight and adiposity in mice [107,108]. Studies have shown that 
ATRA represses obesity and insulin resistance in a type 2 diabetic animal model, through activation of 
proliferation-activated receptor δ (PPARδ) [13]. ATRA-induced body fat loss correlates with the 
activation of brown adipose tissue, reduced adipogenic/lipogenic capabilities, increased capabilities for 
oxidative metabolism in white adipose tissue depots and increased lipid oxidation capacity in skeletal 
muscle and adipocytes [106,109]. Retinoic acid synthesizing enzymes (RALDH) are also involved in 
the regulation of lipid metabolism and high fat diet-induced insulin resistance [110]. The 
polymorphism in the promoter of the CRABP2 gene is associated with increased plasma low-density 
lipoprotein cholesterol (LDL-C) concentrations in familial hypercholesterolemia patients [111]. These 
studies indicate that altered expression/activation of RA signaling closely correlates with the 
development of DM and insulin resistance. J. Clin. Med. 2014, 3 574 
 
 
5. Retinoid Receptor-Mediated Signaling and Diabetic Cardiomyopathy 
5.1. Retinoid Receptor-Mediated Signaling in Cardiac Remodeling 
Cardiac remodeling has a major role in the progression to HF, which is associated with alterations 
in the ventricular structure and function, resulting from myocardial injury, pressure or volume 
overload. At the cellular level, cardiac remodeling is characterized by cardiomyocyte hypertrophy, 
fibroblast hyperplasia accompanied by an increase in collagen deposition within the interstitial matrix 
(fibrosis) and cell death. It is well known that RA signaling is required for cardiac   
development [112–115]. Changes in RA homeostasis (lacking or excess of RA) result in severe 
malformations during cardiogenesis, suggesting that a precise tissue concentration of RA is 
indispensable for the proper induction of signaling pathways important for normal myocardial cell 
growth and differentiation in early embryonic stages. RA signaling has been implicated in the 
regulation of cell differentiation, proliferation and apoptosis [116,117], and a substantial body of 
knowledge has accumulated on its role in the regulation of cardiomyocyte growth, apoptosis and 
cellular function in response to various pathophysiological stimuli. Using an in vitro cultured 
cardiomyocyte model, we and others have demonstrated that RA suppresses myocardial cell growth in 
response to hypertrophic stimuli, including cyclic stretch, angiotensin II (Ang II), endothelin-1 and 
phenylephrine [118–121]. Ang II-induced cardiac fibroblast growth and collagen secretion are also 
inhibited by RA [122]. Chronic RA treatment attenuated tobacco smoke exposure-induced cardiac 
hypertrophy and LV dysfunction in rats [123] and prevented medial thickening of intramyocardial and 
intrarenal arteries and ventricular fibrosis during the development of hypertension in SHR 
(Spontaneously Hypertensive)  rats [124]. In a rat model of myocardial infarction, coronary   
occlusion-induced LV morphological (hypertrophy) and functional changes were improved by RA 
treatment [125]. Using a chronic rat pressure-overload model, our group demonstrated that RA inhibits 
cardiomyocyte apoptosis and fibrosis and improves both systolic and diastolic heart function, through 
the inhibition of the oxidative stress-induced activation of MAP kinase pathways and the expression of 
renin-angiotensin system (RAS) components [126]. These studies suggest that activation of the 
RAR/RXR signaling pathway has an important role in preventing the transition from compensatory 
hypertrophy to heart failure. 
Diabetic cardiomyopathy represents a distinct structural and functional disorder of the myocardium 
characterized by cardiac hypertrophy and diastolic heart failure at the early stage, progressing to overt 
systolic heart failure at the later stage. Using in vitro primary cultured cardiomyocytes, we have 
demonstrated that high glucose-induced apoptosis and reactive oxygen species (ROS) generation was 
prevented by both RAR and RXR agonists. Silencing the expression of RARα and RXRα, by small 
interference RNA, promoted apoptosis under normal conditions and significantly enhanced high 
glucose-induced apoptosis [8]. Using an in vivo type 2 diabetic animal model, we provided additional 
evidence supporting a role of RARα and RXRα in the diabetes-induced development of cardiac 
remodeling. We have shown that chronic treatment with the RARα selective ligand, Am580, and the 
RXR selective ligand, LGD1069, significantly improved diastolic dysfunction and attenuated LV 
hypertrophy, fibrosis, apoptosis and inflammatory responses in ZDF rats [7]. Our data indicate that J. Clin. Med. 2014, 3 575 
 
 
RA/RAR/RXR-mediated signaling may serve as an alternative therapeutic target in the prevention and 
treatment of diabetic cardiomyopathy. 
5.2. Mechanisms Involved in Retinoid Receptor Signaling Regulated Diabetic Cardiomyopathy 
5.2.1. Activation of RAR/RXR Signaling Improves Cardiac Insulin Signaling and  
Glucose/Lipid Metabolism 
In type 1 and type 2 DM, glucose uptake, glycolysis and pyruvate oxidation are impaired. 
Additionally, a lack of insulin function augments lipolysis and the release of fatty acids (FA) from 
adipose tissue. Derangements in cardiac lipid and glucose metabolism are becoming recognized as an 
early event in the deterioration of heart function in diabetes. Hyperglycemia is the main driving force 
at all stages of diabetic cardiomyopathy. It triggers various adaptive and maladaptive responses, which 
lead synergistically to the development of heart failure [29,127]. Under normal physiological 
conditions, glucose is one of the major carbohydrates utilized by the heart. In type 1 diabetic animals, 
reduced GLUT gene and protein expression compromises cardiac glucose uptake and oxidation [128]. 
In obese or type 2 diabetic animals, cardiac glucose uptake is reduced as a consequence of reduced 
GLUT4 protein and impaired insulin signaling [129,130]. The impaired glucose uptake forces 
cardiomyocytes to rely less on glucose metabolism and more on β-oxidation of free fatty acids (FA) 
for energy production. This dramatic shift results in the loss of metabolic flexibility and decreased 
cardiac efficiency in diabetic heart. Moreover, augmented FA oxidation increases lipid deposition and 
promotes insulin resistance. Lipid accumulation within cardiomyocytes is associated with impaired 
contractile function [131]. FA metabolism also generates a number of toxic intermediates that accumulate 
in myocardial cells, resulting in lipotoxicity, and contributes to the initiation and development of diabetic 
cardiomyopathy [132–136]. Oxidative stress, the imbalance between reactive oxygen species production 
and the breakdown by endogenous antioxidants, has been implicated in the onset and progression of 
cardiovascular diseases, such as congestive heart failure and diabetic cardiomyopathy [137,138]. Studies 
have shown that hyperglycemia significantly enhances free radical formation and mitochondrial generation 
of superoxide, which increases oxidative stress and activates cellular signal transduction and cardiac cell 
death, leading to diabetic cardiomyopathy [8,22,139,140]. Increased lipid accumulation and FA   
β-oxidation in diabetic myocardium also leads to overwhelming generation of ROS, which is associated 
with impaired insulin signaling and the development of heart dysfunction [141,142]. As such, insulin 
resistance, increased FA and hyperglycemia can be considered triggers for the cardiac phenotype in 
diabetes. An understanding of the cellular effects and mechanisms of these metabolic disturbances on 
cardiomyocytes will be important in predicting the structural and functional cardiac consequences and in 
developing therapeutic approaches for the treatment of DM-induced cardiac remodeling. 
A number of studies have shown that RA lowers plasma glucose levels and improves insulin 
resistance in adipocytes, skeletal muscle and liver tissues [14,15,83–89]. Our group further provided 
evidence that the activation of RAR/RXR signaling improves cardiac glucose metabolism in ZDF  
rats [7]. We demonstrated that activation of RARα and RXR by Am580 and LGD1069 not only 
improved systemic glucose homeostasis, but also had a significant effect on cardiac glucose 
metabolism. Impaired Akt/GSK3β insulin signaling and decreased gene expression of GLUT1, J. Clin. Med. 2014, 3 576 
 
 
GLUT4, aldolase A and hexokinase 2, in ZDF rat hearts, was improved by Am580 or LGD1069 
treatment, indicating that the activation of RAR and RXR signaling rescued the impaired cardiac 
insulin signaling and promoted glucose transportation and utilization. Diabetes-induced cardiac 
oxidative stress, apoptosis and activation of MAP kinases and NF-κB pathways were inhibited by 
Am580 and LGD1069. Thus, it is likely that the beneficial effect of Am580 or LGD1069 on diabetic 
cardiomyopathy is mediated at least partially by reducing glucotoxicity-induced cardiac oxidative 
stress and activation of apoptotic signaling. RAR and RXR-mediated signaling has an important role in 
the regulation of lipid metabolism and the development of obesity. However, the functional role of 
RAR and RXR in the regulation of cardiac lipid metabolism remains unclear. Previous studies have 
shown that ATRA suppresses hyperlipidemia and obesity and blocks adipogenesis, by enhancing FA 
oxidation and energy dissipation, through ATRA-induced activation of PPARβ/δ and RAR in 
adipocytes and liver [13,106]. We observed that ATRA suppressed body weight gain and increased 
cardiac FA β-oxidation in ZDF rats, following two weeks of treatment. Am580 had a similar effect on 
inhibiting body weight gain, cardiac FA uptake, β-oxidation and intracardiac lipid accumulation in 
ZDF rats, following 16 weeks of treatment [7]. These data suggest that ATRA and Am580 may alter 
substrate metabolism in diabetic heart, through rebalancing the utilization between glucose and FA, 
which further leads to improvement in cardiac efficiency and function. Though Am580 had a favorable 
effect on cardiac lipid metabolism, it had no effect on the increased plasma cholesterol and triglyceride 
levels. Am580, a selective agonist of RARα, is not an activator of PPARβ/δ, and thus, the mechanisms 
whereby Am580 regulates cardiac lipid metabolism and suppresses obesity may be different than those 
of ATRA. Compared to ATRA and Am580, LGD1069 further promoted body weight gain and 
hyperlipidemia following 16 weeks of treatment and significantly increased intracardiac lipid 
deposition in ZDF rat hearts. This is not consistent with previous studies, which have shown that RXR 
ligands, including LGD1069, decrease triglycerides and increase HDL levels in db/db or ob/ob   
mice [102,143]. It has been described that RXR can form permissive heterodimers with PPARs, the 
farnesoid-X-receptor and liver-X-receptors (LXR) and that these can be activated by both   
RXR-specific and partner-specific ligands [144]. We have observed that PPARα and LXR are 
activated by LGD1069 and that these receptors are also involved in the regulation of lipid   
metabolism [145,146]. The effect of LG1069 on cardiac lipid homeostasis we observed may be 
regulated not only through activation of RXR, but also PPAR and LXR. Therefore, studies with a 
receptor-subtype-specific ligand and receptor knockout models are critical to understand the 
downstream mechanisms involved in RAR/RXR-mediated metabolic signaling pathways. 
5.2.2. RAR/RXR Signaling in the Regulation of Cardiac NF-κB-Mediated Inflammatory Responses 
Cardiac inflammation is one of the diverse mechanisms that are involved in the progression of 
diabetic cardiomyopathy [147–149]. Sustained increases in the levels of pro-inflammatory cytokines 
and chemokines, such as tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) 
and interleukin-6 (IL-6), could directly and indirectly cause cardiac tissue injury, such as myocardial 
fibrosis, necrosis and apoptosis, which inevitably leads to cardiac diastolic and subsequent systolic 
dysfunction [150,151]. Pro-inflammatory cytokine expression is under the control of the ubiquitous 
and inducible transcription factor, NF-κB (nuclear factor-kappa B), which is activated by a variety of J. Clin. Med. 2014, 3 577 
 
 
pathological stimuli, such as inflammatory cytokines, hyperglycemia, elevated free fatty acid levels in 
plasma, oxidative stress, angiotensin II, lipoproteins and anoxia [152,153]. Inactive NF-κB is primarily 
located in the cytoplasm in association with the inhibitor of κB (IκB). Following exposure to various 
stimuli, IκB is phosphorylated by IκB kinases (IKKs) and degraded by the ubiquitin proteasome 
pathway. A large body of evidence suggests that NF-κB activation occurs in a sustained manner in 
diabetes, in association with elevated blood glucose levels and inflammation [154–157]. The 
involvement of NF-κB in diabetic cardiomyopathy has been demonstrated in several studies on 
diabetic rat hearts [6,7,158,159]. Retinoids act as potent anti-inflammation agents that exert beneficial 
responses in the cardiovascular system [160,161]. Vitamin A and its metabolites inhibit several   
types of inflammatory reactions [162,163], and activated NF-κB signaling is associated with an 
increased inflammatory response in vitamin A deficiency [164–166]. The activation of RXR inhibits 
high glucose-induced upregulation of inflammation, by suppressing the activation of the NADPH 
oxidase-NF-κB pathway in human endothelial cells [167]. These data suggest that there is an 
interaction between RAR/RXR signaling and the NF-κB-mediated inflammatory pathway. We have 
demonstrated that the activation of RAR and RXR inhibits the activation of NF-κB and   
NF-κB-mediated gene expression of IL-6, TNF-α and MCP-1, in vitro and in vivo [6,7], indicating that 
the protective effects of RAR and RXR ligands on cardiomyocytes are mediated (at least in part) 
through the regulation of NF-κB signaling. The molecular mechanisms by which RA inhibits the 
activation of NF-κB appears to involve the inhibition of phosphorylation of IKK/IκBα and degradation 
of IκBα, through activation of PP2A (protein phosphatase 2A). The interactions between RAR/RXR 
and NF-κB signaling may have important implications in understanding the mechanisms involved in the 
development of diabetic cardiomyopathy. 
5.2.3. RAR/RXR Signaling in the Regulation of the Renin-Angiotensin System 
The renin-angiotensin system (RAS) and its primary effector peptide, angiotensin II (Ang II), is a 
key regulatory system in blood pressure and volume homeostasis and has an essential role in the 
pathophysiology of heart failure. The RAS has been an important drug target for therapeutic 
intervention: Ang II receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEi) and 
renin inhibitors reduce heart failure-related morbidity and mortality [168,169]. Accumulating evidence 
suggests that RAS blockade also has favorable effects on the parameters of glucose metabolism and 
the incidence of diabetes [170]. Expression/activation of the RAS has been implicated in the 
development of diabetic cardiomyopathy. Abnormal production of Ang II is associated with a high 
index of cardiomyocyte apoptosis in human and animal models of diabetes [171,172]. Hyperglycemia 
stimulates cardiomyocyte production of Ang II via an upregulation of most of the cellular components 
of the RAS [172–176]. The interaction between RA signaling and the RAS has previously been 
reported [126,177–179]. RA negatively regulates renal RAS components in rats with experimental 
nephritis [177]. Downregulation of AT1R mRNA and the repressed Ang II-stimulated AT1R promoter 
activity are observed in RA-treated vascular smooth muscle cells [178,180]. It has been shown that RA 
downregulates the expression of AT1R and upregulates ACE2 in SHR hearts, which is accompanied by 
a decrease in blood pressure [179,181]. Our group also demonstrated that the increased plasma level of 
Ang II, upregulated gene expression of cardiac and renal renin, angiotensinogen (AGT), ACE and AT1R J. Clin. Med. 2014, 3 578 
 
 
are inhibited by ATRA in pressure overloaded rats and mechanically stretched cardiomyocytes [126], 
indicating that RA signaling is involved in regulating RAS components during the development of 
cardiac remodeling. We have reported recently that hyperglycemia-induced apoptosis and ROS 
production are inhibited by the AT1R blocker, indicating that Ang II-activated AT1R signaling 
contributes to hyperglycemia-induced cellular injury [8]. ATRA inhibited high glucose- and   
Ang II-induced cell apoptosis and ROS production. High glucose-induced gene expression of AGT, 
renin, AT1R and intracardiac Ang II production were significantly inhibited by ATRA. On the other 
hand, silencing the expression of RARα or RXRα increased the basal level of the gene expression of 
AGT and dramatically increased AGT expression in combination with high glucose stimulation. Our 
results suggest that a certain level of expression of RARα and RXRα is required in the regulation of 
the expression of AGT, under normal and hyperglycemic conditions, and that RARα/RXRα 
heterodimer-mediated signaling negatively regulates RAS components and AT1R-mediated signaling 
events. By inhibiting the rate-limiting step in the renin-angiotensin cascade, RA signaling might have 
some advantages over the RAS inhibitors widely used in the clinic. 
5.2.4. Does Impaired RAR/RXR Signaling Contribute to the Development of DCM? 
The high degree of conservation of RAR and RXR across vertebrates and specific patterns of 
expression during embryogenesis and in adult tissues suggests that each receptor performs a specific 
function [182]. Targeted disruption of RAR and RXR, mainly RARα and RXRα in the embryonic 
stage, resulted in early postnatal or embryonic lethality and heart failure [183,184], suggesting that 
RARα and RXRα are the two main receptor subtypes that are involved in the regulation of cardiomyocyte 
differentiation and function. It has been reported that decreased cardiac expression of RXRα is involved in 
the altered myocardial metabolic phenotype in severe heart failure and that downregulation of RXRα may be 
responsible for impairment in free fatty acid oxidative pathways in the failing heart [185,186]. We have 
recently demonstrated that nuclear expression of RARα and RXRα was significantly downregulated in high 
glucose-stimulated cardiomyocytes and in diabetic rat myocardium [7,8,187]. High glucose stimulation also 
repressed physiological doses of RA-induced transcriptional activity of RAR and RXR, suggesting that a 
relative “RA-resistance” developed in response to hyperglycemia. Whether the alteration of RAR/RXR 
signaling is directly associated with the development of diabetes-induced cardiac remodeling remains 
unknown. We have observed that silencing the expression of RARα and RXRα in cardiomyocytes promotes 
high glucose-induced expression/activation of cardiac RAS components and apoptosis in vitro [8]. To 
further understand the role of RARα and RXRα in the regulation of cellular function in adult 
cardiomyocytes, in response to pathological stimuli, we generated tamoxifen-inducible RARα and RXRα 
cardiac-specific knockout mice (RARαKO and RXRαKO). Cardiac-specific gene deletion of RARα and 
RXRα results in diastolic dysfunction, which is associated with increased oxidative stress and   
apoptosis [188]. These results suggest that RARα and RXRα-mediated signaling is required to preserve 
normal cardiomyocyte function and that impairment of RAR/RXR signaling may accelerate the 
development of heart failure in response to pathological stimuli. Understanding the mechanisms underlying 
the impaired cardiac expression/activation of RARα and RXRα will be important in determining the novel 
mechanisms leading to heart failure. J. Clin. Med. 2014, 3 579 
 
 
Retinoid receptor transcriptional activity is regulated by factors both intrinsic and extrinsic to the receptor 
complex. Although ligand binding is thought to be the primary means of activation of RAR and RXR, the 
transcriptional activity of RAR and RXR is also modulated by protein kinase-mediated phosphorylation and 
degradation [189]. RARα and RXRα contain multiple phosphorylation sites (Figure 2) and are substrates for 
a variety of serine/threonine kinases, including PKA, PKC, Cdk7 and MAP kinases [70,72,190–192]. 
Phosphorylation of RXRα at serine 260, a consensus MAP kinase site, results in the attenuation of   
ligand-dependent transactivation by the vitamin D3 receptor/RXRα complex [193]. Stress-induced 
phosphorylation of RXRα, through MAPK kinase 4 (MKK4) and JNK, results in the suppression of retinoid 
signaling in COS-7 cells (derived from CV-1 simian cells transformed by an origin-defective mutant of 
SV40) [74,194]. JNK activation by oxidative stress suppresses retinoid signaling through proteasomal 
degradation of RARα in hepatic cells [195]. These data suggest that oxidative stress/MAP kinases-regulated 
phosphorylation/degradation of RAR and RXR may have an important role in pathological stimuli-induced 
impairment of RAR/RXR signaling. We have recently reported that high glucose induces serine 
phosphorylation of RARα and RXRα in cardiomyocytes and that inhibition of intracellular ROS generation 
and activation of the JNK pathway prevents the downregulated expression and transcriptional repression of 
RARα and RXRα in cardiomyocytes. On the other hand, H2O2 stimulation or activation of JNK suppressed 
the expression and ligand-induced promoter activity of RARα and RXRα [187]. Based on these data, it is 
likely that diabetes-induced oxidative stress and activation of JNK promotes degradation and transcriptional 
inhibition of RARα and RXRα, through phosphorylation of RARα and RXRα at specific phosphorylation 
sites. Interestingly, silencing the expression of RARα and RXRα in cardiomyocytes promoted the activation 
of the JNK pathway in vitro [187] and in vivo (in the hearts of RARαKO and RXRαKO mice) [188], 
suggesting that impaired RAR/RXR signaling and oxidative stress/the JNK pathway form a vicious circle, 
which may significantly contribute to diabetes-induced cardiac remodeling (Figure 4).  Identifying the 
phosphorylation site that is specifically linked to JNK-mediated degradation and transcriptional inhibition of 
RARα and RXRα will have functional significance in understanding the mechanism of DCM and in 
developing a therapeutic strategy for management. 
6. Conclusions 
Retinoic acid and RAR/RXR-mediated signaling are increasingly recognized as mediators of 
diabetes and obesity. Impaired RAR/RXR signaling may contribute to the development of diabetic 
cardiomyopathy and diastolic heart failure. Experimental data have provided strong evidence that RAR 
and RXR function as important transcriptional regulators in the development of diabetes-induced 
cardiac remodeling and heart failure, through the regulation of the cardiac renin-angiotensin system, 
glucose/lipid metabolism and oxidative stress associated signaling pathways. Therefore, retinoic acid 
and RAR/RXR-mediated signaling may represent a novel target for developing therapeutic approaches 
for the treatment and prevention of diastolic heart failure and DCM. J. Clin. Med. 2014, 3 580 
 
 
Figure 4. Schematic of the interaction between diabetes mellitus (DM), JNK and impaired 
RAR/RXR signaling in DCM. Mechanisms of DM-induced oxidative stress and JNK 
activation in the regulation of phosphorylation/transcriptional inhibition of RARα and 
RXRα and the development of DCM are proposed. 
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